“EVALUATION OF CENTRAL NERVOUS SYSTEM ACTIVITY OF AYURVEDIC
FORMULATION COGNIUM IN EXPERIMENTAL ANIMAL MODELS”
M. Pharm Dissertation Protocol
Submitted to
Rajiv Gandhi University of Health Sciences, Karnataka
Bangalore – 560 041
By
MR. AJMAL. N
Under the Guidance of
Mr. Abhilash D
Assistant Professor
Department of Pharmacology,
Shree Devi College of Pharmacy
Airport Road, Kenjar Village,
Malavoor Panchayath
Mangalore – 574142.
1
RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES,
BANGALORE, KARNATAKA,
ANNEXURE II
PROFORMA FOR REGISTRATION OF SUBJECTS
1.
Name of the Candidate
and Address
AJMAL .N
Nelliyote house.
Paleri p.o, Kuttiady,
Kozhikkode (Dist.),
Kerala. Pin – 673508.
2.
Name of the Institute
Shree Devi College of Pharmacy,
Airport Road, Kenjar Village,
Malavoor Panchayat,
Mangalore-574 142
Karnataka.
3.
Course of Study and Subject
Master of Pharmacy in Pharmacology
4.
Date of Admission to Course
November 2012
5.
Title of the Topic:
“EVALUATION OF CENTRAL NERVOUS SYSTEM ACTIVITY OF
COGNIUM IN EXPERIMENTAL ANIMAL MODELS”
2
6.
BRIEF RESUME OF THE INTENDED WORK:
6.1 Need of study:
Central Nervous System control all the human body functions.
The
neurodegeneration of this system leads to disorders like Alzheimer’s disease,
Parkinson’s disease, depressive disorders, epilepsy, insomnia1. Memory is special
facility of brain, which retains the events developed during the process of learning,
and both are mediated by nervous system2. Once memories have been stored in the
brain, it becomes the part of brain –process mechanism when it will recall in future3.
Learning and memory are closely related, all learning involves memory but all
memory not involves to learning4.
Probably learning and memory are most evolutionary advantageous
developments for human. These are interesting but ill-understood subjects. By
utilizing past experience due to learning and its storage in memory one can get
success and avoid failure5.
Alzheimer’s disease is progressive loss of memory and cognitive function in
middle age individuals. (Cognition: that means by which one is aware of the process
of thinking and perceiving. It involves an awareness of sensation and usually its
cause. Mental component consist of cognitive changes.) Symptoms of Alzheimer’s
disease are–memory is failed for recent events, lack of spontaneous activity and
initiative with loss of intellectual functions, loss of spatial orientations1.
In recent years, attempts have been made to develop drugs for treatment of
dementia and attention deficit disorders to improve memory and learning2. These
agents are commonly referred as Nootropic agents or cognition enhancers. The
indications of cognition enhancers are senile dementia of Alzheimer type and multi
infarct dementia, common symptoms of elderly, dizziness and memory disturbances
and mental retardation in children, learning defects, attention deficit disorder6.
Ayurveda, an ancient Indian system of medicine had reported various plants
with the caliber of memory enhancing activity. Based on the same concept, several
herbal formulations have been widely marketed, claiming to be useful in memory
3
disorders. As there are no fixed guidelines in the indigenous system of medicine, to
evaluate the retention of the potency by the formulation; we planned to evaluate
ayurvedic formulation Cognium tablet for its CNS activity. Cognium tablet is a
product of Charak pharma consisting of Mukta Pishtee: Abhrak Bhasma, Soya
(Glycine soja) and Extracts of the following:
Jala Brahmi (Bacopa monnieri), Brahmi (Centella asiatica), Ashwagandha
(Withania somnifera), Arjun (Terminalia arjuna), Jyotishmati (Celastrus
paniculatus), Jaiphal (Myristica fragrans), Tagar (Valeriana wallichi), Vacha
(Acorus calamus).
6.2 Review of literature:
COGNIUM - Corrects Cognitive Insufficiency. Benefits of using
Cognium formulation are- Preserve and enhance cognitive functions, Slows down
the process of degeneration of neurons through antioxidants, Increase circulation to
the CNS and Provide protection to nervous system by acting as adaptogenic against
stress.
COMPOSITION7
Each coated tablet contains,
Mukta Pishtee: 5 mg, Abhrak Bhasma: 25 mg, Soya (Glycine soja): 50 mg and
Extracts of the following:
Jala Brahmi (Bacopa monnieri): 200 mg, Brahmi (Centella asiatica): 100 mg
Ashwagandha (Withania somnifera): 100 mg, Arjun (Terminalia arjuna): 50 mg
Jyotishmati (Celastrus paniculatus): 50 mg, Jaiphal (Myristica fragrans): 25 mg.
Tagar (Valeriana wallichi): 20 mg, Vacha (Acorus calamus): 20 mg.
The literature review of these individual components of the formulation have
reveled the following:

Mukta Pishtee8
Mukta Pishtee is an Ayurvedic medicine, prepared from Pearl. It is used in
Ayurvedic treatment of diarrhea with bleeding, Mania, Psychosis and depression. It
acts as cardiac tonic, antihypertensive and other , excessive burning sensation,
gastritis, fever.
4

Abhrak Bhasma9
Abhrak Bhasma is an Ayurvedic medicine, prepared from Mica. It is used in
Ayurvedic treatment of asthma, urinary disorders, skin diseases etc. t is used in the
treatment of digestive impairment, malabsorption syndrome, Disease due to Kapha
Dosha, Asthma, bronchitis, Fever, Bleeding disorders, Cough, Cold, Urinary
disorders, diabetes, Anaemia, Skin diseases, splenic disorders, ascites, Helminthiasis,
etc. It also useful in rejuvenation treatment. Pharmacological investigation proves
Hepatoprotective10 action of abhrak bhasma.

Soya (Glycine soja) 11
Glycine soja, or wild soybean belongs to the family Fabaceae or Leguminosae.
The saponin content glycine soja shows hypocholesterolaemic, haemolytic,
immunostimulatory, and antitumourigenic and chemoprotective activities, Effects on
Cognitive Function12, 13.

Jala Brahmi (Bacopa monnieri)
Bacopa monnieri belongs to the family Scrophularaceae reported to contain
Brahmine, Herpestine, Saponins and betulic acid was used as nervine tonic,
antiepilepitic, diuretic to reduce stress induced anxiety, nootropic, antipyretic, antiinflammatory, analgesic, sedative and adaptogenic actions. It possessing antidepressant effect14 and neuroprotective effects in epilepsy15. Further neuroprotective
effects are said to be due to anti-oxidant properties which suppresses neuronal
oxidative stress as observed in Alzheimer’s disease16. It is also reported to be
potential herb for safely enhancing cognitive performance in the aged.17

Brahmi (Centella asiatica)
Centella asiatica, Commonly known as mandukparni is a perennial herbaceous
creeper belonging to the family Umbellifere (Apiceae). The primary active
constituents of Centella asiatica are saponins (also called triterpenoids), which
include asiaticosides, in which a trisaccharide moiety is linked to the aglycone asiatic
acid, madecassoside and madasiatic acid. Apart from wound healing, the herb is
recommended for the treatment of various skin conditions such as leprosy, lupus,
psoriasis, diarrhoea, fever, amenorrhea, diseases of the female genitourinary tract
and also for relieving anxiety and improving cognition. Pharmacological
5
investigation reveals and anxiolytic properties18, Antidepressant properties18,
Antiepileptic properties19, Cognitive and antioxidant properties20.

Ashwagandha (Withania somnifera)
Withania somnifera belongs to family Solanaceae reported to contain
somniferin, resin, fat, phytosterol, ipuranol, withaolide and withaferin A is used as
nervine tonic, astringent, adaptogenic, febrifuge, sedative, hypnotic, anthelmintic
and diuretic. When this herb has been subjected for its neuropharmacologcal
investigation, AchE inhibitory effect of methanolic and successive water extracts,
indicating its potential to influence cognition21. In animal model of Alzheimer’s
disease its oral administration ameliorated neuronal dysfunction22. It also has
adoptogenic activity in chronic stress rat models23. Glycowithanolides, one of its
constituent have anxiolytic and anti-depressant activity which can be compared with
imipramine24.

Terminalia arjuna (Arjuna)
In ayurvedic medicine, bark of Terminalia arjuna is therapeutically used as
cardio-tonic. But, apart from that it is also used to treat hypertension, tumors,
diabetes and anemia. Pharmacological investigations reported in animal models
include anti oxidant activity25 and cardio protective activity26.

Jyotishmati (Celastrus paniculatus)
Celastrus paniculatis, another indigenous folklore medicinal herb of this
formulation is reported to have spectrum of CNS activity mainly on cognition in
several animal models of learning and memory. Further chronic treatment (oral) of
oil of Celastrus paniculatis reversed the impairment of spatial memory without
affecting of cholinergic neurotransmission27. And Kumar et al have correlated effect
on cognition by virtue of anti-oxidant properties of aqueous extracts28.
Neuroprotective of water soluble extract have been reported in neuronal cultures of
brain by virtue of their anti-oxidant properties29.

Jaiphala (Myristica fragrans)
Myristica fragrans well known Indian household spice have been reported to
possess several neuropharmacological properties. Anti-depressant activity of nhexane extracts involving adrenergic, dopaminergic and seretonergic system30. Nhexane fraction of acetone insoluble part of petroleum ether extract and its acetone
6
soluble portion is reported to possess anticonvulsant, significant behavioral effects,
anxiogenic, sedative and cholinesterase inhibiting properties31 indicating wide
spectrum of CNS effects.

Tagar (Valeriana wallichi)
Valeriana wallachi (Tagara), Indian Valerian34 has long been used in
Ayurveda (Charak Samhita and Susruta) and Unani systems of medicine, which
describe its use in obesity, skin disease, insanity, epilepsy and snake poisoning. It is
folklore medicinal herb having main therapeutic use as tranquilizer. Attempts have
been made to study its pharmacological activity on central nervous system. It is
found to useful in stress management32, reported to increase in short term memory33
and also have role in saving injured neuron of the hippocampus in depressed rats.

Vacha (Acorus calamus)
Acorus calamus is one of folklore herbs of Asian continent. Investigation on
roots and rhizome of this plant points to its influence on CNS. Some of the reported
activities are anti-depressant activity of Ethanolic extract of rhizome, alcoholic
extract of this plant possessing wide activity on CNS like sedative, spontaneous
motor activity, tranquilizing effect and amphetamine induced hyperactivity35,
methanolic extract of rhizome improving memory and cognition36, neuroprotective
effect, methanolic and ethanolic extract in noise induced stress and AchE inhibitory
activity of hydro alcoholic extra.
6.3 Objective of study:
The objective of the proposed study is to evaluate the possible CNS effects of
ayurvedic formulation COGNIUM using different experimental animal models.

To explore the influence on various CNS disorders like epilepsy, depression,
anxiety, neuralgia, motor incoordination, motility using experimental models :
Anticonvulsant activity
 Maximum Electroshock induced Seizures (MES).
 Isoniazid Induced convulsion.

Antidepressant activity
 Forced Swim Test (FST).
7
 Tail Suspension Test (TST).

Antianxiety activity
 Elevated Plus-maze.

Analgesic activity
 Hot Plate Method.
 Acetic acid induced writhing assay.

Motor incoordination activity
 Rota rod Apparatus.

Motility test
 Actophotometer.

Behavioral studies

Effect on sleep activity
 KetamineHCL induced sleeping.
7.
MATERIALS AND METHODS:
7.1 Source of Data:
Data will be obtained from laboratory based studies by using Swiss albino
mice (25-30g) and albino wistar rats(160-220g) of either sex, maintained at room
temperature having free access to food (std pellet diet), water ad libitum. These
studies will be carried out in intact animal and isolated brain that will be supported
by biochemical data and behavioral studies.
7.2 Method of Collection of Data:
Materials: Ayurvedic formulation COGNIUM (CHARAK PHARMA), Chemicals and
reagents will be procured from standard companies.
7.3 Acute Toxicity Test:
The acute oral toxicity study was performed according to the OPPTS guidelines
(Office of Prevention, Pesticide and Toxic Substance) following the limit test
procedure37.
8
7.4 EXPERIMENTAL MODELS:
 Anticonvulsant activity:
Maximum Electroshock-induced Seizures (MES)38:
Rats will be divided into 4 groups (n=6).
o Group I - Control (vehicle only).
o Group II – Standard -Phenytoin (25mg/kg i.p)39.
o Group III - COGNIUM low dose.
o Group IV – COGNIUM high dose.
The animals will receive a current of 45 mA for 0.2 sec duration through
electroconvulsiometer using corneal electrodes, after 60 min of oral administration of
COGNIUM, vehicle or phenytoin. The incidence and duration of extensor tonus will be
noted. A complete abolition of hind limb tonic extension will be considered as 100%
protection.
INH Induced Seizures38:
Albino wistar rats (150-200 g) were divided into four groups with six animals in
each group. All the treatments were administered intraperitonially 30 min prior to the
administration of INH (300 mg/kg). Animals that did not convulse within 30 min were
considered as protected. The number of rat protected in each group was expressed in
terms of percentage. In the INH treated group, the animals were monitored for 60 min,
and the percent protection was determined. In unprotected animals, the latency to first
convulsion and the durations of convulsions were recorded
 Antidepressant activity :
Forced swim test40:
Mice will be divided into 4 groups (n=6).
o Group I - Control (vehicle only)
o Group II - Standard–Imipramine (20 mg/kg i.p)39.
o Group III – COGNIUM low dose.
o Group IV - COGNIUM high dose.
FST will be performed in glass jar. This test consists of two parts, an
9
initial training period of 15 min followed by actual test for 5 min duration 24 h later.
Mice will be individually forced to swim inside a vertical borosilicate glass cylinder
(height: 40 cm; diameter: 15 cm; containing 15 cm height of water maintained at 25o
C). The mice from each group II, III, IV will be placed in the cylinder 24 h later after
two doses of COGNIUM and imipramine (20mg/kg) respectively and their activity
will be recorded. The recordings will be analyzed to find the duration of immobility,
swimming behavior and climbing behavior in the 5 min test period using stopwatch.
An animal will be judged to be immobile whenever it remains floating passively in
the water in a slightly hunched but upright position, its nose just above the surface,
with no additional activity other than that necessary to keep its head above water.
Swimming is defined as active movement throughout the swim chamber, which
includes crossing into another quadrant. Climbing activity (also termed thrashing)
consist of upward directed movements of the forepaws along the side of the swim
chamber. The data obtained will be compared between standard and test.
Tail Suspension Test (TST)40:
The grouping of animals will be similar to that of FST. The total duration of
immobility induced by tail suspension will be measured according to the described
method as a facile means of evaluating potential antidepressants. Mice will be
suspended on the edge of a table 50 cm above the floor by the adhesive tape placed
approximately 1 cm from the tip of the tail. Immobility time will be recorded during a 6
min period. Animal will be considered to be immobile when it did not show any
movement of body and hanged passively.
 Antianxiety activity:
Elevated Plus-maze41:
Mice will be divided into 4 groups (n=6).
o Group I - Control (vehicle only)
o Group II – Standard - Diazepam (4mg/kg i.p)39.
o Group III – COGNIUM low dose.
o Group IV – COGNIUM high dose.
The wooden maze consists of two open arms (length 50cm X breadth 10 cm) and
10
two closed arms of the same size (height 40 cm). The arms of the same type are opposite
to each other, with a central square of 10 cm. The maze is elevated to a height of 50 cm
above the floor.
Behavioral assessment:
Each animal will be tested initially in plus maze. On the 10th day of drug or
vehicle administration, 60 minutes after the last dose, each animal will be placed in the
centre square of the plus maze, facing one of the open arms. The number of entries into
and the time spent in open and closed arms and the number of rears in each arm in a
five-minute period will be noted.
 Analgesic Activity:
Hot Plate Method42:
Mice were divided into 4 groups (n=6).
o Group I - Control (vehicle only)
o Group II -Standard - Pentazocine (10mg/kg i.p)39.
o Group III - COGNIUM low dose.
o Group IV - COGNIUM high dose.
The parameter evaluated will be the latency time for paw licking and jumping
response after exposure on surface of hot plate. The standard used will be Pentazocine
(10mg/kg, i.p.) The hot plate temperature will be kept at (550C) and the cut off time will
be 20sec. The data obtained will be compared and studied.
Acetic-acid induced writhing assay42:
Mice will be divided into 4 groups (n=6).
o Group I - Control (vehicle only)
o Group II – Standard - Diclofenac sodium (10mg/kg i.p)39.
o Group III - COGNIUM low dose.
o Group IV - COGNIUM high dose.
Analgesic activity of the COGNIUM will be studied by reduction of acetic acid
induced writhing in mice. Thirty minutes after the administration of COGNIUM or
11
standard diclofenac sodium (10 mg/kg, i.p.), the animals will receive acetic acid (0.6%,
10 ml/kg ip). The number of abdominal contractions (writhing) and stretching with a
jerk of the hind limb will be counted for 15 min after administering acetic acid, and
percent inhibition will be calculated as follows:
% inhibition = (1 - WT/ WC) × 100
Where, WT is the writhings in drug-treated mice
and WC is the writhings in control mice.
 Motor incoordination activity:
Rota rod Apparatus43:
Mice will be divided into 4 groups (n=6).
o Group I - Control (vehicle only)
o Group II – Standard - Diazepam (4mg/kg i.p)39.
o Group III – COGNIUM low dose.
o Group IV - COGNIUM high dose.
The effect on motor coordination will be assessed using Rota rod apparatus. The
animals will be trained to remain for 3 min on the Rota rod rotating at a speed of 25
rpm. On the next day either vehicle or COGNIUM will be administered orally and their
ability to remain on the rotating rod will be assessed before and after the oral
administration. The fall off time from the rod will be noted for each animal. The data
will be compared and studied.
Motility test43:
The grouping of animals will be similar to that of motor incoordination test. Thirty
min after drug administration, the spontaneous locomotor activity will be recorded using
an activity cage, Actophotometer with automatic counting of animal movements on the
cage floor. The loco motor count for each animal will be recorded for 5 minutes at 30
minute interval for 2 h. The data obtained will be compared and studied.
Behavioural effect43:
Mice will be divided into 3 groups (n=6).
o Group I - control (vehicle only).
12
o Group II - COGNIUM low dose.
o Group III - COGNIUM high dose.
Behavioral effect of COGNIUM will be assessed by the method. After treatment
with COGNIUM, the animals will be observed after 30 min of administration up to 2 hr
for the behavioral changes. Prior to COGNIUM, the behavioral pattern of the vehicle
treated mice will be studied. The observation parameters consist of body position,
locomotion, rearing, reparation, lighting reflex and lacrimation. The data obtained will
be compared and studied.
 Effect on sleep activity:
Ketamin HCL-induced sleeping time43:
Mice will be divided into 3 groups (n=6).
o Group I - Control (vehicle)
o Group II – Standard –Ketamine HCL (100mg/kg i.p)39.
o Group III - COGNIUM low dose.
o Group IV – COGNIUM high dose.
Ketamine HCL (100mg/kg i.p39) will be injected 30 min before oral administration
for all groups. The time elapsed between loss and recovery of the lighting reflex will be
noted and taken as sleeping time. The data obtained will be compared and studied.
7.5 Does the study require any investigation or interventions to be conducted on
patients or the human or animals? If so please describe briefly:
Yes.Study requires evaluation on experimental animals. The effect of Standard/
Ayurvedic formulation COGNIUM will be studied on various parameters as stated
above in objectives of the study.
7.6 Has ethical clearance been obtained from your institute
Ethical Committee approval letter is enclosed.
13
8.
LIST OF REFERENCES:
1.
Thomson RF. The brain: A neuroscience primer. 3rd ed. New York: Worth
publisher; 2000.
2.
Chatterjee CC, Human physiology. Nov. edition. Medical Allied Agency
Calcutta 1997;(2)5:264.
3.
Guyton and Hall, Textbook of Medical Physiology, Saunders an imprint of
Elsevier. 2006;Ed (11):45:557.
4.
Bijlani R L, understanding medical physiology, Jaypee Brothers Medical
Publishers (P) Ltd. New Delhi 2004;Ed (3):16.3:861-64.
5.
Andrew Davies, Asa G H Blakeley, Cecil Kidd, Human Physiology, Churchill
Livingston London 2001;4:352.
6.
Tripathi K D, Essentials of Medical Pharmacology, Jaypee Brothers Medical
Publishers (P) Ltd. New Delhi 2001, Ed (4)32:480-82.
7.
http://www.charak.com/product/Cognium-Tablet
8.
Http://ayurmedinfo.com/2012/07/02/mukta-pishti-benefits-dosage-ingredientsside-effects/
9.
Http://ayurmedinfo.com/2012/07/02/abhraka-bhasma-benefits-dosageingredients-side-effects/
10. Buwa S, Patil S, Kulkarni PH, Kanase A. Hepatoprotective action of abhrak
bhasma, an ayurvedic drug in albino rats against hepatitis induced by CCl4.
Indian J Exp Biol. 2001 Oct;39(10):1022-27.
11. Http://www.ars-grin.gov/cgi-bin/npgs/html/taxon.pl?17801#common
12. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW,
van der Schouw YT. Effect of soy protein containing isoflavones on cognitive
function, bone mineral density, and plasma lipids in postmenopausal women: a
randomized controlled trial. JAMA. 2004 Jul 7;292(1):65-74.
13. Donna Kritz-Silverstein, PhD, Denise von Mühlen, MD, PhD, Gail A. Laughlin,
PhD, and Ricki Bettencourt, MS) Effects of Dehydroepiandrosterone
Supplementation on Cognitive Function and Quality of Life: The DHEA and
14
Well-Ness (DAWN) Trial J Am Geriatr Soc. 2008 July;56(7):1292–98.
14. Zhou T, Shen YH, Zhan C, Su J, Liu RH, Zhang WD. Triterpene saponins from
Bacopa monnieri anti-depressant effects in mice models. J Nat Prod 2007;
70:652-5.
15. Paulose CS, Chathu F, Reaskhan, Kumar K. Neuroprotective role of Bacopa
monnieri extract in epilepsy and effect of glucose supplementation during
hypoxia: glutamate receptor gene expression. Neurochem Res. 2007; 33:166371.
16. Limpeanehab N, Jalpan S, Rattanakarunas, phrumpittayarat W, Ingkaninan K.
neuroprotective effect of Bacopa monnieri on bêta-amyloid induced cell death in
primary cortical culture. J Ethnopharmacol 2008;1:112-7.
17. Calabrese C, Gregory WL, Leo M, Kraemer D, Bone k, Oken B. Effects of a
standardized Bacopa monnieri Extract or cognitive performance, anxiety and
depression in elderly: a randomized double blind placebo controlled trial. J
Altern complement Med.2008;14:707-3.
18. Veerendra Kumar MH, Gupta YK. Effect of different extracts of Centella
asiatica on cognition and markers of oxidative stress in rats. J Ethnopharmacol.
2002; 79:253–60.
19. Ganachari MS, Babu V, Katare S. Neuropharmacology of an extract derived
from Centella asiatica. Pharm Biol. 2004;42:246–52.
20. Veerendra Kumar MH, Gupta YK. Effect of Centella asiatica on cognition and
oxidative stress in an intracerebroventricular streptozotocin model of
Alzheimer's disease in rats. Clin Exp Pharmacol Physiol. 2003;30:336–42.
21. Vinutha B, Prashant D, Salma K, Sreeja SL, Pratiti D, Padmoja R et al.
Screening of selected indian medicinal plants for acetylcholine esterase
inhibitory activity. J Ethnopharmacol 2007;109:359-63.
22. Kaboyama T, Tohda C, Komastu K.Withanoside IV and its active metabolite
somione, attenuates Abeta (25-35) induced neurodegeneration. Eur J
Neurodegeneration 2006;23:1417-26.
23. Bhattacharya SK, Munyanandan AV. Adaptogenic activity of Withania
15
somnifera Dunn an experimental study using rat model of chronic stress.
Pharmacol Biochem Behav 2003;75:545-56.
24. Singh B, Saxena AK, Chandan BK, Gupta DK, Bhutani KK, Anand KK.
Adaptogenic activity of a novel withanolide free aqueous fraction from roots of
Withania somnifera Dunn. Phytother Res 2001;15:311-8.
25. Raghavan B, Kumari SK. Effect of Terminalia arjuna bark on anti-oxidant status
in liver and kidney of alloxan diabetic rats. Indian J Physiol Pharmacol 2006;50:
133-42.
26. Singh G, Singh AT, Abraham A, Bhat B, Mukherjee A, Verma R, Agarwal SK
et al. Protective effects of Terminalia arjuna against Doxorubicin induced cardio
toxicity. J Ethnopharmacol 2008;117:123-9.
27. Gattu M, Boss KL, Terry AV Jr, Baccafusco JJ. Reversal of scopolamine
induced deficits in navigational memory performance in seed oil of Celastrus
paniculatis. Pharmacol Biochem Behav 1995;57: 793-9.
28. Kumar MH, Gupta YK. Anti-oxidant property of Celastrus paniculatis wild a
possible mechanism for enhancing cognition. Phytomedicine 2002;9:302-11.
29. Godkar PB, Gordan RK, Ravindran A, Doctor BP. Celastrus paniculatis seed
water soluble extracts protect cultured rat neuronal cells from hydrogen peroxide
induced oxidative injury. Fitoterpia 2003;74:658-9.
30. Dhingra D, Sharma A. Anti-depressant like activity of n-hexane extract of
nutmeg (Myristica fragrans) seeds in mice. J Med Food; 9:84-9.
31. Dhingra D, Parle M, Kulkarni SK. Comparative brain cholinesterase activity of
G.glabra, Myristica fragrans ascorbic acid and metrifonate in mice. J Med Food
2006;9:281-3.
32. Bhattacharya D, Jarna V, Debanath PK, Sur TK. Initial exploratory observational
pharmacology of Valeriana wallichi on stress management: a clinical report.
Nepal Med Coll J 2007;9:31-9.
33. Rehni AK, Pantlya HS, Shri R, Singh M. Effects of chlorophyll and aqueous
extracts of Bacopa monnieri and Valeriana wallichi on ischemia and reperfusion
induced cerebral injury in mice. Indian J Exp Biol 2007;45:764-9.
34. http://en.wikipedia.org/wiki/Valeriana_wallichii
16
35. Oh MH, Houghton RJ, Whang WK, Cho JH. Screening of Korean herbal
medicines used to improve cognition function for anti-cholinesterase activity.
Phytomedicine 2004;11:544-8.
36. Shukla PK, Khanna VK, Ali MM, Maurya R, Khan MY, Srimal RC.
Neuroprotective effect of Acorus calamus against middle cerebral artery
occlusion induced ischemia in rats. Human Exp Toxicol 2006;25:187-94.
37. http:/www.epa.gov/opptsfrs.2010 Nov 15.
38. Swinyard EA, Brown WC, Goodman LS. Comparative assay of antiepileptic
Drugs in mice and rats. J Pharmacol Exp Ther 1952;106:319-30.
39. Kulkarni SK. Handbook of experimental pharmacology. 3rd ed. New Delhi:
Vallabh prakashan; 2010.
40. Dhingra D, Sharma A. Evaluation of antidepressant like activity in glycyrrhizin
in mice. Indian J Pharmacol 2005 Dec;37(7):390-94.
41. Krishna HNG, Sangha RB, Misra N, Pai MRSM. Antianxiety activity of NR
ANX-C, a polyherbal preparation in rats. Indian J Pharmacol. 2006
Oct;38(5):330-5.
42. Pawar JC, Khairnar PP, Chaudhari SR. Central nervous system activity of
Different extracts of Lagenaria siceraria leaves parts. IJPRD 2010 Sep; 2(7):9.
43. Achliya GS, Wadodkar SG, Dorle AK. Evaluation of sedative and
anticonvulsant activities of Unmadnashak Ghrita. J Ethnopharmacol.2004;
94(1):77-83.
9.
SIGNATURE OF
THE CANDIDATE :
(AJMAL. N)
10.
REMARKS OF THE GUIDE:
The project is viable and is recommended for clearance and approval.
11.
Name and Designation of
17
Abhilash D
11.1 Guide
Assistant Professor
Dept. Of Pharmacology,
Shree Devi collage of pharmacy,
Mangalore-574142.
Karnataka
11.2 Signature
Dr. Jagadish V Kamath.
11.3 Head of the Department
Professor
Dept. Of Pharmacology,
Shree Devi collage of pharmacy,
Mangalore-574142.
Karnataka.
11.4 Signature
12.
12.1 Remarks of the Principal:
The Project is recommended and requested for clearance and approval.
12.2 Signature
Dr. Jagadish V Kamath.
Principal
Shree Devi collage of pharmacy,
Mangalore-574142.
Karnataka.
18